The UK government is trialling a pharmaceutical payment system to incentivise companies to develop drugs for resistant infections.
The trial will test a subscription-style model that pays pharmaceutical companies upfront for access to drugs based on their usefulness to the NHS. It will be led by the National Institute for Health and Care Excellence (NICE), NHS England and NHS Improvement.
The Department of Health and Social Care said on 9 July that it hoped the system would make it more attractive for companies to invest in creating drugs, as they will be paid for the drug even if it is stored for reserves.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.